Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Yu Hu, Yongrui Zhang, Jialin Gao, Xin Lian & Yuantao Wang. (2020) The clinicopathological and prognostic value of CD44 expression in bladder cancer: a study based on meta-analysis and TCGA data. Bioengineered 11:1, pages 572-581.
Read now
Read now
Articles from other publishers (23)
Antonio J. Montero‐Hidalgo, Jesús M. Pérez‐Gómez, Antonio J. Martínez‐Fuentes, Enrique Gómez‐Gómez, Manuel D. Gahete, Juan M. Jiménez‐Vacas & Raúl M. Luque. (2022) Alternative splicing in bladder cancer: potential strategies for cancer diagnosis, prognosis, and treatment. WIREs RNA 14:3.
Crossref
Crossref
Fonthip Laohavisudhi, Titikorn Chunchai, Natnicha Ketchaikosol, Wacharaporn Thosaporn, Nipon Chattipakorn & Siriporn C. Chattipakorn. (2022) Evaluation of CD44s, CD44v6, CXCR2, CXCL1, and IL-1β in Benign and Malignant Tumors of Salivary Glands. Diagnostics 12:5, pages 1275.
Crossref
Crossref
Suzan M. Talaat, Sabrine A Ahmad, Nour El Hoda S. Ismael & Lubna O. Abdel-Salam. (2021) Immunohistochemical expression of stem cell markers ALDH1 and CD44 in urothelial carcinoma of the urinary bladder. Comparative Clinical Pathology 30:4, pages 559-564.
Crossref
Crossref
Debanwita Roy Burman, Shalini Das, Chandrima Das & Rahul Bhattacharya. (2021) Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance. Molecular Biology Reports 48:1, pages 897-914.
Crossref
Crossref
Alessandro Apollo, Valerio Ortenzi, Cristian Scatena, Katia Zavaglia, Paolo Aretini, Francesca Lessi, Sara Franceschi, Sara Tomei, Carlo Alberto Sepich, Paolo Viacava, Chiara Maria Mazzanti & Antonio Giuseppe Naccarato. (2019) Molecular characterization of low grade and high grade bladder cancer. PLOS ONE 14:1, pages e0210635.
Crossref
Crossref
Pamela Bielli, Valentina Panzeri, Rossano Lattanzio, Simona Mutascio, Marco Pieraccioli, Elisabetta Volpe, Vincenzo Pagliarulo, Mauro Piantelli, Antonella Giannantoni, Savino M. Di Stasi & Claudio Sette. (2018) The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients with Non–muscle-Invasive Bladder Cancer. Clinical Cancer Research 24:21, pages 5422-5432.
Crossref
Crossref
Rita Azevedo, Janine Soares, Cristiana Gaiteiro, Andreia Peixoto, Luís Lima, Dylan Ferreira, Marta Relvas-Santos, Elisabete Fernandes, Ana Tavares, Sofia Cotton, Ana Luísa Daniel-da-Silva, Lúcio Lara Santos, Rui Vitorino, Francisco Amado & José Alexandre Ferreira. (2018) Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer. Talanta 184, pages 347-355.
Crossref
Crossref
Anja Mortensen, Diana Spiegelberg, Anna-Karin Haylock, Hans Lundqvist & Marika Nestor. (2018) Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy. International Journal of Oncology.
Crossref
Crossref
Rita Azevedo, Andreia Peixoto, Cristiana Gaiteiro, Elisabete Fernandes, Manuel Neves, Luís Lima, Lúcio Lara Santos & José Alexandre Ferreira. (2017) Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?. Oncotarget 8:53, pages 91734-91764.
Crossref
Crossref
Marwa M. Serag El-Dien, Rania A. Abdallah & Fouad Zanaty. (2017) Role of ALDH1a and CD44 in transitional and squamous cell carcinomas of urinary bladder. Egyptian Journal of Pathology 37:1, pages 137-144.
Crossref
Crossref
Roland Seiler, Htoo Zarni Oo, Davide Tortora, Thomas M. Clausen, Chris K. Wang, Gunjan Kumar, Marina Ayres Pereira, Maj S. Ørum-Madsen, Mette Ø. Agerbæk, Tobias Gustavsson, Mie A. Nordmaj, Jamie R. Rich, Nada Lallous, Ladan Fazli, Sherry S. Lee, James Douglas, Tilman Todenhöfer, Shaghayegh Esfandnia, Dulguun Battsogt, John S. Babcook, Nader Al-Nakouzi, Simon J. Crabb, Igor Moskalev, Bernhard Kiss, Elai Davicioni, George N. Thalmann, Paul S. Rennie, Peter C. Black, Ali Salanti & Mads Daugaard. (2017) An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. European Urology 72:1, pages 142-150.
Crossref
Crossref
Noha M. El-Anwar, Radwa Orieby, Safinaz H. El-Shorbagy, Ahlam M. Abo El-Enain & Samir N. Mina. (2016) Immunohistochemical study of cancer stem cell markers ‘OCT4’ and ‘CD44’ in correlation with COX2 in urinary bladder carcinoma. Egyptian Journal of Pathology 36:2, pages 139-148.
Crossref
Crossref
Julieta Afonso, Lúcio L. Santos, Vera Miranda-Gonçalves, António Morais, Teresina Amaro, Adhemar Longatto-Filho & Fátima Baltazar. (2015) CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance. Molecular Carcinogenesis 54:11, pages 1451-1466.
Crossref
Crossref
Bangli Hu, Wei Luo, Rui-Ting Hu, You Zhou, Shan-Yu Qin & Hai-Xing Jiang. (2015) Meta-Analysis of Prognostic and Clinical Significance of CD44v6 in Esophageal Cancer. Medicine 94:31, pages e1238.
Crossref
Crossref
Nut Koonrungsesomboon, Anita Carolle Wadagni & Evaristus Chibunna Mbanefo. (2015) Molecular markers and Schistosoma-associated bladder carcinoma: A systematic review and meta-analysis. Cancer Epidemiology 39:4, pages 487-496.
Crossref
Crossref
Ilaria Lucca, Michela de Martino, Tobias Klatte & Shahrokh F. Shariat. (2015) Novel Biomarkers to Predict Response and Prognosis in Localized Bladder Cancer. Urologic Clinics of North America 42:2, pages 225-233.
Crossref
Crossref
Xiao-Jin Wu, Xiao-Dong Li, Hanze Zhang, Xiaofei Zhang, Zhong-Hua Ning, Yong-Mei Yin & Ye Tian. (2015) Clinical significance of CD44s, CD44v3 and CD44v6 in breast cancer. Journal of International Medical Research 43:2, pages 173-179.
Crossref
Crossref
Caio M. Moura, Jose PontesJrJr, Sabrina T. Reis, Nayara I. Viana, Denis R. Morais, Nelson Dip, Betina Katz, Miguel Srougi & Katia R. M. Leite. (2015) Expression profile of standard and variants forms of CD44 related to prostate cancer behavior. The International Journal of Biological Markers 30:1, pages 49-55.
Crossref
Crossref
Shuang Zhao, Jin-Lan He, Zhi-Xin Qiu, Nian-Yong Chen, Zhuang Luo, Bo-Jiang Chen & Wei-Min Li. (2014) Prognostic Value of CD44 Variant exon 6 Expression in Non-Small Cell Lung Cancer: a Meta-analysis. Asian Pacific Journal of Cancer Prevention 15:16, pages 6761-6766.
Crossref
Crossref
Jun Shi, Zhou Zhou, Wen Di & Ningli Li. (2013) RETRACTED ARTICLE: Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer 13:1.
Crossref
Crossref
Bernd Bürkle, Nadine K. Notscheid, Jan Scheich, Lukas Hefler, Clemens B. Tempfer, Reinhard Horvat & Günther A. Rezniczek. (2013) Spread of endometriosis to pelvic sentinel lymph nodes: gene expression analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology 169:2, pages 370-375.
Crossref
Crossref
Gang Wu, Yuanhang Zhou, Tianyi Li, Jingjing Guo & Zhongwen Zhou. (2013) Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma. Journal of International Medical Research 41:3, pages 816-824.
Crossref
Crossref
Zhouming Deng, Guangfeng Niu, Lin Cai, Renxiong Wei & Xiaolei Zhao. (2013)
The Prognostic Significance of CD44V6, CDH11, and
-Catenin Expression in Patients with Osteosarcoma
. BioMed Research International 2013, pages 1-9.
Crossref
Crossref